Invivyd Inc.

27/08/2024 | Press release | Distributed by Public on 27/08/2024 10:17

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.